Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of 2-Deoxy-D-Glucose as an adjunctive therapy to standard of care, in comparison to standard of care alone, in the Acute Treatment of moderate to severe COVID -19 patients

X
Trial Profile

A Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of 2-Deoxy-D-Glucose as an adjunctive therapy to standard of care, in comparison to standard of care alone, in the Acute Treatment of moderate to severe COVID -19 patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2-deoxy-D-glucose (Primary)
  • Indications COVID-19 pneumonia
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 17 May 2021 New trial record
    • 08 May 2021 According to a Ministry of defense (DRDO) media release, phase IIa was conducted in six hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients.
    • 08 May 2021 Status changed from recruiting to completed, according to a Ministry of defense (DRDO) media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top